Abstract
The rapidly increasing prevalence of type 2 diabetes (T2D) is motivating an intensive search for biomarkers to identify individuals at risk for developing the disease. It has been established that both genetic and environmental factors are influential in the progression to T2D. Currently, the number of genetic loci implicated in T2D susceptibility is more than 65 and together, these factors explain only about 10% of the risk. At this time, prediction models using genetic information do not perform substantially better than models based on routine clinical measures. The search for new biomarkers must integrate new, independent factors beyond the static genome that are influenced by environmental conditions. This search must also recognize the heterogeneity of T2D and seek new biomarkers of potential subtypes and confounding conditions such as obesity. Modulation of gene expression by epigenetic modifications and the action of microRNAs are being recognized as critical processes affecting T2D risk. This review provides an update on the current state of genetic biomarkers of T2D susceptibility and examines how epigenetic modulation of some new and established diabetes susceptibility genes can identify increased risk and provide biomarkers for early detection and therapeutic monitoring.
Keywords: Diabetes, pre-diabetes, genetics, epigenetics, microRNA, GWAS, biomarker.
Current Diabetes Reviews
Title:DNA Methylation and MicroRNA-Based Biomarkers for Risk of Type 2 Diabetes
Volume: 12 Issue: 1
Author(s): Thomas M. O’Connell and Christina A. Markunas
Affiliation:
Keywords: Diabetes, pre-diabetes, genetics, epigenetics, microRNA, GWAS, biomarker.
Abstract: The rapidly increasing prevalence of type 2 diabetes (T2D) is motivating an intensive search for biomarkers to identify individuals at risk for developing the disease. It has been established that both genetic and environmental factors are influential in the progression to T2D. Currently, the number of genetic loci implicated in T2D susceptibility is more than 65 and together, these factors explain only about 10% of the risk. At this time, prediction models using genetic information do not perform substantially better than models based on routine clinical measures. The search for new biomarkers must integrate new, independent factors beyond the static genome that are influenced by environmental conditions. This search must also recognize the heterogeneity of T2D and seek new biomarkers of potential subtypes and confounding conditions such as obesity. Modulation of gene expression by epigenetic modifications and the action of microRNAs are being recognized as critical processes affecting T2D risk. This review provides an update on the current state of genetic biomarkers of T2D susceptibility and examines how epigenetic modulation of some new and established diabetes susceptibility genes can identify increased risk and provide biomarkers for early detection and therapeutic monitoring.
Export Options
About this article
Cite this article as:
M. O’Connell Thomas and A. Markunas Christina, DNA Methylation and MicroRNA-Based Biomarkers for Risk of Type 2 Diabetes, Current Diabetes Reviews 2016; 12 (1) . https://dx.doi.org/10.2174/1573399811666150515125557
DOI https://dx.doi.org/10.2174/1573399811666150515125557 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Development and the Importance of Ethnicity: Lessons from Heart Failure Management and Implications for Hypertension
Current Pharmaceutical Design Cell-Penetrating Peptides as a Potential Drug Delivery System for Effective Treatment of Diabetes
Current Pharmaceutical Design Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450
Current Drug Metabolism Fanconi-Bickel Syndrome - A Congenital Defect of Facilitative Glucose Transport
Current Molecular Medicine Carnosine and Kidney Diseases: What We Currently Know?
Current Medicinal Chemistry Novel Imaging Techniques in Acute Kidney Injury
Current Drug Targets Electronegative LDL: An Active Player in Atherogenesis or a By- Product of Atherosclerosis?
Current Medicinal Chemistry Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy
Current Drug Targets Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness
Current Drug Targets Blood Platelet Reactivity and its Pharmacological Modulation in (People with) Diabetes Mellitus
Current Pharmaceutical Design A Possible Link of Gut Microbiota Alteration in Type 2 Diabetes and Alzheimer’s Disease Pathogenicity: An Update
CNS & Neurological Disorders - Drug Targets n-3 Polyunsaturated Fatty Acids as Signal Transduction Modulators and Therapeutical Agents in Cancer
Current Signal Transduction Therapy Interaction Between Genetic Polymorphisms in Renin-Angiotensin System (RAS) and Therapeutic Efficacy of RAS Blockade in IgA Nephropathy
Current Pharmacogenomics Chromium-Picolinate Therapy in Diabetes Care: Individual Outcomes Require New Guidelines and Navigation by Predictive Diagnostics
Infectious Disorders - Drug Targets CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews Integrative Neurochemistry and Neurobiology of Social Recognition and Behavior Analyzed with Respect to CD38-Dependent Brain Oxytocin Secretion
Current Topics in Medicinal Chemistry The Therapeutic Potential of Rutin for Diabetes: An Update
Mini-Reviews in Medicinal Chemistry The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment
Current Pharmaceutical Design